Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Open accessThe DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Abstract
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could lead to astrocyte/microglia imbalance, glutamatergic overproduction and excitotoxic neuronal damage (Sanacora et al., 2008) with impact on synapse functionality.”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, increased glutamate levels has been associated with mechanisms involved in stress and depression, such as neuro-inflammatory process, decreased levels of neurotrophic factors, diminished neurogenesis, and neuroplasticity impairment [116,117].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [117]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rapidly acting antidepressants were discovered in the glutamatergic system (Berman et al., 2000;Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Several classes of antidepressants as well as SSRIs are known to exert action on the glutamate system by influencing NMDA or AMPA receptor transcription (Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Glia also play an important role in regulating the synthesis and reuptake of glutamate and thereby influence synaptic function and morphology16,17.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Although most patients with mood disorders receive some benefit from available treatment”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 1×
“, and is approved for the treatment of moderate to severe Alzheimer's disease, in which it has been shown to enhance cognition and minimize clinical deterioration in patients with Alzheimer's disease, vascular dementia or mixed dementi”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 1
- Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).
Cited by
Items 101–200 of 1,000
NMDA Receptor Activity in Neuropsychiatric Disorders
Lakhan, S. E., Caro, M., & Hadzimichalis, N. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00052 · Cited by 151
Arnone, D., Mumuni, A. N., Jauhar, S., Condon, B., & Cavanagh, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.016 · Cited by 150
“Ionotropic receptors are N-methyl-D-aspartate (NMDA), Kainate (KA) and α-amino-3 hydroxy5-methyl-4-isoxazolepropionic acid (AMPA) whilst metabotropic receptors are Gprotein coupled (GPCRs, mGlu) (Swanson et al., 2005)(Sanacora et al., 2008).”
BackgroundTang, J., Xue, W., Xia, B., Ren, L., Tao, W., Chen, C., Zhang, H., Wu, R., Wang, Q., Wu, H., et al. (2015) · Scientific Reports · doi:10.1038/srep13573 · Cited by 149
Voineskos, D., Blumberger, D. M., Zomorrodi, R., Rogasch, N. C., Farzan, F., Foussias, G., Rajji, T. K., & Daskalakis, Z. J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.032 · Cited by 149
Esterlis, I., DellaGioia, N., Pietrzak, R. H., Matuskey, D., Nabulsi, N., Abdallah, C. G., Yang, J., Pittenger, C., Sanacora, G., Krystal, J. H., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.58 · Cited by 148
Self-citationKrystal, J. H., Abdallah, C. G., Averill, L. A., Kelmendi, B., Harpaz-Rotem, I., Sanacora, G., Southwick, S. M., & Duman, R. S. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0829-z · Cited by 145
Self-citationSex differences in fear extinction
Velasco, E. R., Florido, A., Milad, M. R., & Andero, R. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.020 · Cited by 145
Dysfunctional hippocampal activity affects emotion and cognition in mood disorders
Femenía, T., Gómez-Galán, M., Lindskog, M., & Magara, S. (2012) · Brain Research · doi:10.1016/j.brainres.2012.03.053 · Cited by 143
Antidepressants act directly on astrocytes: Evidences and functional consequences
Czéh, B., & Benedetto, B. D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.017 · Cited by 143
Wang, Q., Charych, E. I., Pulito, V. L., Lee, J. B., Graziane, N. M., Crozier, R. A., Revilla-Sanchez, R., Kelly, M. P., Dunlop, A. J., Murdoch, H., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.87 · Cited by 141
Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression
Feyissa, A. M., Woolverton, W. L., Miguel-Hidalgo, J. J., Wang, Z., Kyle, P. B., Hasler, G., Stockmeier, C. A., Iyo, A. H., & Karolewicz, B. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.018 · Cited by 123
Chitty, K. M., Lagopoulos, J., Lee, R. S. C., Hickie, I. B., & Hermens, D. F. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.007 · Cited by 139
Ketamine for treatment-resistant depression: recent developments and clinical applications
Schwartz, J., Murrough, J. W., & Iosifescu, D. V. (2016) · Evidence Based Mental Health · doi:10.1136/eb-2016-102355 · Cited by 117
Socially responsive effects of brain oxidative metabolism on aggression
Li-Byarlay, H., Rittschof, C. C., Massey, J. H., Pittendrigh, B. R., & Robinson, G. E. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412306111 · Cited by 121
Blockade of Astrocytic Glutamate Uptake in the Prefrontal Cortex Induces Anhedonia
John, C. S., Smith, K. L., Van'T Veer, A., Gompf, H. S., Carlezon, W. A., Cohen, B. M., Öngür, D., & Bechtholt-Gompf, A. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.105 · Cited by 136
Mood-stabilizing drugs: mechanisms of action
Schloesser, R. J., Martinowich, K., & Manji, H. K. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.009 · Cited by 136
Self-citationDysfunctional astrocytic regulation of glutamate transmission in a rat model of depression
Gómez‐Galán, M., Bundel, D. D., Eeckhaut, A. V., Smolders, I. J., & Lindskog, M. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.10 · Cited by 134
Curcumin in Depression: Potential Mechanisms of Action and Current Evidence—A Narrative Review
Ramaholimihaso, T., Bouazzaoui, F., & Kaladjian, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.572533 · Cited by 134
Ampuero, E., Rubio, F. J., Falcon, R., Sandoval, M., Diaz-Veliz, G., Gonzalez, R. E., Earle, N., Dagnino-Subiabre, A., Aboitiz, F., Orrego, F., et al. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.035 · Cited by 132
P2X7 Receptor Signaling in Stress and Depression
Ribeiro, D. E., Roncalho, A. L., Glaser, T., Ulrich, H., Wegener, G., & Joca, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112778 · Cited by 129
“Importantly, increased glutamate levels has been associated with mechanisms involved in stress and depression, such as neuro-inflammatory process, decreased levels of neurotrophic factors, diminished neurogenesis, and neuroplasticity impairment [116,117].”
BackgroundCsölle, C., Baranyi, M., Zsilla, G., Kittel, Á., Gölöncsér, F., Illes, P., Papp, E., Vizi, E. S., & Sperlágh, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066547 · Cited by 128
“, [65], genetic polymorphism [66] and the differential expression of NMDA and AMPA receptor subunits in BPD and MDD patients [67,68]; antidepressant properties of glutamate receptor antagonists and modulators [69]; and the regulation of glutamate receptor subunits by clinically used antidepressants [70,71].”
BackgroundResultCai, K., Nanga, R. P., Lamprou, L., Schinstine, C., Elliott, M., Hariharan, H., Reddy, R., & Epperson, C. N. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.142 · Cited by 128
Stress, glucocorticoids and glutamate release: Effects of antidepressant drugs
Musazzi, L., Racagni, G., & Popoli, M. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.002 · Cited by 128
Ma, X.-C., Dang, Y.-H., Jia, M., Ma, R., Wang, F., Wu, J., Gao, C.-G., & Hashimoto, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056053 · Cited by 114
The receptor hypothesis and the pathogenesis of depression: Genetic bases and biological correlates
Wang, H., Wang, Z., & Chen, N. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105542 · Cited by 126
Lee, E. E., Della Selva, M. P., Liu, A., & Himelhoch, S. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.003 · Cited by 124
“Existing literature suggests that glutamate levels and NMDA receptor mRNA expression are abnormal in patients with major depressive disorder (MDD) and bipolar affective disorder (BPAD), and long-term antidepressant treatment reducesNMDA receptormRNA transcription [15–19].”
BackgroundTargeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Machado-Vieira, R., Salvadore, G., Ibrahim, L., Diaz-Granados, N., & Zarate Jr., C. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168010 · Cited by 118
Self-citationKetamine amplifies induced gamma frequency oscillations in the human cerebral cortex
Shaw, A. D., Saxena, N., E. Jackson, L., Hall, J. E., Singh, K. D., & Muthukumaraswamy, S. D. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.012 · Cited by 122
Eastwood, S. L., & Harrison, P. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.004 · Cited by 122
Laugeray, A., Launay, J., Callebert, J., Surget, A., Belzung, C., & Barone, P. R. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.014 · Cited by 120
Disturbance of the Glutamatergic System in Mood Disorders
Jun, C., Choi, Y., Lim, S. M., Bae, S., Hong, Y. S., Kim, J. E., & Lyoo, I. K. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.1.28 · Cited by 118
Réus, G. Z., Stringari, R. B., Kirsch, T. R., Fries, G. R., Kapczinski, F. P., Roesler, R., & Quevedo, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.11.013 · Cited by 118
Classics in Chemical Neuroscience: Ketamine
Tyler, M. W., Yourish, H. B., Ionescu, D. F., & Haggarty, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00074 · Cited by 106
Salvadore, G., van der Veen, J. W., Zhang, Y., Marenco, S., Machado-Vieira, R., Baumann, J., Ibrahim, L. A., Luckenbaugh, D. A., Shen, J., Drevets, W. C., et al. (2012) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001593 · Cited by 107
Self-citationmGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants
Chaki, S., Ago, Y., Palucha-Paniewiera, A., Matrisciano, F., & Pilc, A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.022 · Cited by 116
Merkl, A., Schubert, F., Quante, A., Luborzewski, A., Brakemeier, E., Grimm, S., Heuser, I., & Bajbouj, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.009 · Cited by 115
Koike, H., Iijima, M., & Chaki, S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.034 · Cited by 114
“Clinical reports have indicated that agents modulating glutamatergic systems ameliorated the depressive states in MDD (Covington et al., 2010; Machado-Vieira et al., 2009; Sanacora et al., 2008).”
BackgroundInfluentialRong, C., Park, C., Rosenblat, J. D., Subramaniapillai, M., Zuckerman, H., Fus, D., Lee, Y. L., Pan, Z., Brietzke, E., Mansur, R. B., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15040771 · Cited by 114
“It is hypothesized that these observed effects of ketamine on neural structures and circuits that are relevant to psychopathology in mood disorders is principally mediated by ketamine-induced effects on AMPA-mediated synaptic plasticity [40].”
BackgroundBalancing histone methylation activities in psychiatric disorders
Peter, C. J., & Akbarian, S. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.02.003 · Cited by 110
Mechanisms of antidepressant resistance
El-Hage, W., Leman, S., Camus, V., & Belzung, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00146 · Cited by 111
Massie, A., Boillée, S., Hewett, S., Knackstedt, L., & Lewerenz, J. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13348 · Cited by 103
Diabetes as a chronic metabolic stressor: Causes, consequences and clinical complications
Reagan, L. P. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.02.004 · Cited by 102
Pharmacological effects of berberine on mood disorders
Fan, J., Zhang, K., Jin, Y., Li, B., Gao, S., Zhu, J., & Cui, R. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13930 · Cited by 110
Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
Open questions in current models of antidepressant action
Tanti, A., & Belzung, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00585.x · Cited by 109
Csölle, C., Andó, R. D., Kittel, Á., Gölöncsér, F., Baranyi, M., Soproni, K., Zelena, D., Haller, J., Németh, T., Mócsai, A., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001933 · Cited by 108
“2001; Toro & Deakin, 2005), the antidepressant properties of glutamate receptor antagonists and modulators (Sanacora et al. 2008) and the regulation of glutamate receptor subunits by clinically used antidepressants (Nowak et al.”
BackgroundInfluentialStress-Induced Changes of Hippocampal NMDA Receptors: Modulation by Duloxetine Treatment
Calabrese, F., Guidotti, G., Molteni, R., Racagni, G., Mancini, M., & Riva, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037916 · Cited by 107
“dates back to several years ago [25], there has been renewed interest in this system because of the observation that NMDA receptor antagonists, such as ketamine, may exert rapid (within 2 hours) antidepressant effects [3,12].”
InfluentialA Hypothesized Role for Dendritic Remodeling in the Etiology of Mood and Anxiety Disorders
Gorman, J. M., & Docherty, J. P. (2010) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.2010.22.3.256 · Cited by 79
Kaltenboeck, A., & Harmer, C. (2018) · Brain and Neuroscience Advances · doi:10.1177/2398212818799269 · Cited by 81
Nasir, M., Trujillo, D., Levine, J. L. S., Dwyer, J. B., Rupp, Z. W., & Bloch, M. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.548505 · Cited by 107
Depression and antidepressants: molecular and cellular aspects
Lanni, C., Govoni, S. M., Lucchelli, A., & Boselli, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0055-x · Cited by 107
Zeni, A. L. B., Zomkowski, A. D. E., Maraschin, M., Rodrigues, A. L. S., & Tasca, C. I. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.041 · Cited by 107
Neuronal nitric oxide synthase and affective disorders
Zhou, Q., Zhu, X., Nemes, A. D., & Zhu, D. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.11.004 · Cited by 106
Lazzaro, V. D., Capone, F., Apollonio, F., Borea, P. A., Cadossi, R., Fassina, L., Grassi, C., Liberti, M., Paffi, A., Parazzini, M., et al. (2013) · Brain stimulation · doi:10.1016/j.brs.2013.01.004 · Cited by 105
Szabo, S. T., Machado-Vieira, R., Yuan, P., Wang, Y., Wei, Y., Falke, C., Cirelli, C., Tononi, G., Manji, H. K., & Du, J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.015 · Cited by 96
Self-citationCantone, M., Bramanti, A., Lanza, G., Pennisi, M., Bramanti, P., Pennisi, G., & Bella, R. (2017) · ASN NEURO · doi:10.1177/1759091417711512 · Cited by 104
Oh, D. H., Son, H., Hwang, S., & Kim, S. H. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.001 · Cited by 103
Hefti, K., Holst, S. C., Sóvágó, J., Bachmann, V., Buck, A., Ametamey, S. M., Scheidegger, M., Berthold, T., Gomez‐Mancilla, B., Seifritz, E., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.030 · Cited by 103
Du, X., Li, J., Li, M., Yang, X., Qi, Z., Xu, B., Liu, W., Xu, Z., & Deng, Y. L. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00393-4 · Cited by 102
The pharmacological properties of antidepressants
Racagni, G., & Popoli, M. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283311acd · Cited by 83
Casarotto, S., Canali, P., Rosanova, M., Pigorini, A., Fecchio, M., Mariotti, M., Lucca, A., Colombo, C., Benedetti, F., & Massimini, M. (2013) · Brain Topography · doi:10.1007/s10548-012-0256-8 · Cited by 89
Biological Mechanisms of Cancer-Induced Depression
Young, K., & Singh, G. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00299 · Cited by 87
From synapse to nucleus: Novel targets for treating depression
Covington, H. E., Vialou, V., & Nestler, E. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.004 · Cited by 98
Neurochemistry of major depression: a study using magnetic resonance spectroscopy
Godlewska, B. R., Near, J., & Cowen, P. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3687-y · Cited by 97
“Particular attention has focused on levels of the amino acid neurotransmitters, glutamate and γ-aminobutyric acid (GABA) because of their postulated role in the pathophysiology of depression (Taylor et al. 2003; Sanacora et al. 2008; Sanacora 2010).”
BackgroundMethodPrins, J., Olivier, B., & Korte, S. M. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594039 · Cited by 97
Iwata, Y., Nakajima, S., Suzuki, T., Keefe, R. S. E., Plitman, E., Chung, J. K., Caravaggio, F., Mimura, M., Graff‐Guerrero, A., & Uchida, H. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.68 · Cited by 97
Wang, Y., Ma, Y., Hu, J., Cheng, W., Jiang, H., Zhang, X., Li, M., Ren, J., & Li, X.-M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.008 · Cited by 97
Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target
Goeldner, C., Ballard, T. M., Knoflach, F., Wichmann, J., Gatti, S., & Umbricht, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.001 · Cited by 96
“, 2010) and imbalanced cortical glutamatergic transmission have been implicated in the pathophysiology of MDD by several groups (Sanacora et al., 2008; Duman and Voleti, 2012) and associatedwith alterations in glial glutamine/glutamate turnover which are most prominent in cortical regions (e.”
BackgroundLyoo, I. K., Yoon, S. J., Musen, G., Simonson, D. C., Weinger, K., Bolo, N., Ryan, C. M., Kim, J. E., Renshaw, P. F., & Jacobson, A. M. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.86 · Cited by 96
A Novel Family of Negative and Positive Allosteric Modulators of NMDA Receptors
Costa, B. M., Irvine, M. W., Fang, G., Eaves, R. J., Mayo-Martin, M. B., Skifter, D. A., Jane, D. E., & Monaghan, D. T. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174144 · Cited by 95
Zomkowski, A. D. E., Engel, D., Gabilan, N. H., & Rodrigues, A. L. S. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.07.011 · Cited by 94
THERAPEUTIC MECHANISMS OF KETAMINE
Mihaljević, S., Pavlović, M., Reine, K., & Čačić, M. (2020) · Psychiatria Danubina · doi:10.24869/psyd.2020.325 · Cited by 94
Cruceanu, C., Alda, M., Nagy, C., Freemantle, E., Rouleau, G. A., & Turecki, G. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000363 · Cited by 93
Anterior cingulate Glutamate–Glutamine cycle metabolites are altered in euthymic bipolar I disorder
Soeiro-de-Souza, M. G., Henning, A., Machado-Vieira, R., Moreno, R. A., Pastorello, B. F., da Costa Leite, C., Vallada, H., & Otaduy, M. C. G. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.09.020 · Cited by 86
State-Dependent Partial Occlusion of Cortical LTP-Like Plasticity in Major Depression
Kühn, M., Mainberger, F., Feige, B., Maier, J. G., Mall, V., Jung, N. H., Reis, J., Klöppel, S., Normann, C., & Nissen, C. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.310 · Cited by 93
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Self-citationLudka, F. K., Zomkowski, A. D. E., Cunha, M. P., Dal-Cim, T., Zeni, A. L. B., Rodrigues, A. L. S., & Tasca, C. I. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.005 · Cited by 92
Acute d-serine treatment produces antidepressant-like effects in rodents
Malkesman, O., Austin, D. R., Tragon, T., Wang, G., Rompala, G., Hamidi, A. B., Cui, Z., Young, W. S., Nakazawa, K., Zarate, C. A., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001386 · Cited by 92
Self-citationHow Oxidative Stress Induces Depression?
Ji, N., Lei, M., Chen, Y., Tian, S., Li, C., & Zhang, B. (2023) · ASN NEURO · doi:10.1177/17590914231181037 · Cited by 92
Memantine: a comprehensive review of safety and efficacy
Kavirajan, H. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802528420 · Cited by 84
Targeting glial physiology and glutamate cycling in the treatment of depression
Valentine, G. W., & Sanacora, G. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.008 · Cited by 87
Self-citationGuo, M., Lu, Y., Garza, J. C., Li, Y., Chua, S. C., Zhang, W., Lu, B., & Lu, X.-Y. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.9 · Cited by 83
The PSD-95/nNOS complex: New drugs for depression?
Doucet, M. V., Harkin, A., & Dev, K. K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.005 · Cited by 92
Schmidt, M. V., Trümbach, D., Weber, P., Wagner, K., Scharf, S. H., Liebl, C., Datson, N., Namendorf, C., Gerlach, T., Kühne, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4668-10.2010 · Cited by 91
“There is by now substantial evidence for the glutamate hypothesis of depression (Hashimoto, 2009), and novel drugs acting on the glutamatergic system show a high potential as antidepressants (Sanacora et al., 2008; Machado-Vieira et al., 2009).”
BackgroundInvolvement of NMDAR2A tyrosine phosphorylation in depression‐related behaviour
Taniguchi, S., Nakazawa, T., Tanimura, A., Kiyama, Y., Tezuka, T., Watabe, A. M., Katayama, N., Yokoyama, K., Inoue, T., Izumi‐Nakaseko, H., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.300 · Cited by 91
Szewczyk, B., Poleszak, E., Sowa-Kućma, M., Wróbel, A., Słotwiński, S., Listos, J., Wlaź, P., Cichy, A., Siwek, A., Dybała, M., et al. (2010) · Amino Acids · doi:10.1007/s00726-009-0412-y · Cited by 91
Novel antidepressant drugs: Beyond monoamine targets
Gonda, X., Döme, P., Neill, J. C., & Tarazi, F. I. (2021) · CNS Spectrums · doi:10.1017/s1092852921000791 · Cited by 91
Hashimoto, K., Bruno, D., Nierenberg, J., Marmar, C. R., Zetterberg, H., Blennow, K., & Pomara, N. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.8 · Cited by 90
Neuroinflammation and glial cell activation in mental disorders
Almeida, P. G. C., Nani, J. V. S., Oses, J. P., Brietzke, E. M., & Hayashi, M. A. F. (2019) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2019.100034 · Cited by 90
Synaptic plasticity model of therapeutic sleep deprivation in major depression
Wolf, E., Kühn, M., Normann, C., Mainberger, F., Maier, J. G., Maywald, S., Bredl, A., Klöppel, S., Biber, K. P. H., van Calker, D., et al. (2015) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.11.003 · Cited by 90
Hunt, M. J., & Kasicki, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113495117 · Cited by 83
Bettio, L. E. B., Cunha, M. P., Budni, J., Pazini, F. L., Oliveira‐Giacomelli, Á., Colla, A. R. D. S., & Rodrigues, A. L. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.06.021 · Cited by 89
Yang, Y., Ju, W., Zhang, H., & Sun, L. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00229 · Cited by 75
Lee, P. H., Perlis, R. H., Jung, J.-Y., Byrne, E. M., Rueckert, E., Siburian, R., Haddad, S., Mayerfeld, C. E., Heath, A. C., Pergadia, M. L., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.95 · Cited by 88
Zeni, A. L. B., Camargo, A., & Dalmagro, A. P. (2017) · Steroids · doi:10.1016/j.steroids.2017.07.006 · Cited by 87
Ketamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions
Salvadore, G., & Singh, J. B. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12103 · Cited by 81
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 85
Cuccurazzu, B., Bortolotto, V., Valente, M. M., Ubezio, F., Koverech, A., Canonico, P. L., & Grilli, M. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.121 · Cited by 85
Yamanaka, H., Yokoyama, C., Mizuma, H., Kurai, S., Finnema, S. J., Halldin, C., Doi, H., & Onoe, H. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.112 · Cited by 84
Zinc in the Glutamatergic Theory of Depression
Mlyniec, K. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150115220617 · Cited by 84
Metadata
- Authors
- Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K.
- Affiliations
- Yale University (US)
- National Institutes of Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-05
- Volume
- 7
- Issue
- 5
- Pages
- 426-437
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC2715836
- OpenAlex
- W2074907255
- Cited by
- 894
- References
- 186
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 33 · 2023: 44 · 2022: 36 · 2021: 44 · 2020: 56 · 2019: 43 · 2018: 40 · 2017: 50 · 2016: 63 · 2015: 70 · 2014: 59 · 2013: 56 · 2012: 68
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (K02MH076222, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- glutamatergic system, mood disorders, antidepressants, neuroplasticity, glutamatergic agents, monoaminergic systems, rapid-acting antidepressants, drug development
- MeSH terms
- Animals, Glutamates, Humans, Psychotropic Drugs, Excitatory Amino Acid Antagonists, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.